Raphael Pinaud
CEO
AT
Antharis Therapeutics, Inc.
The company develops therapeutic monoclonal antibodies and antibody-drug conjugates specifically targeting cancer and neurological diseases. By providing targeted treatments, it aims to improve the quality of life for patients suffering from serious illnesses.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$5.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The company develops therapeutic monoclonal antibodies and antibody-drug conjugates specifically targeting cancer and neurological diseases. By providing targeted treatments, it aims to improve the quality of life for patients suffering from serious illnesses.